News
-
Aptar Pharma announced that it has acquired OINDP specialist CDMO Mod3 Pharma (formerly Enteris Biopharma). According to Mod3’s web site, Enteris was created in 2013 with assets and personnel from Unigene, which manufactured Fortical calcitonin… Read more . . .
-
Hong Kong-based Guangdong Hengrui Pharmaceuticals’s parent company Jiangsu Hengrui Pharmaceuticals announced that Guangdong Hengrui has received approval from the Chinese National Medical Products Administration (NMPA) for a clinical trial of its HRS-9821 DPI, which the… Read more . . .
-
Merck has announced that it will acquire Ohtuvarye inhaled ensifentrine maker Verona Pharma for a total of approximately $10 billion. Ohtuvarye, which is delivered via jet nebulizer, was approved by the FDA in June 2024… Read more . . .
-
Evoke Pharma announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a continuation of US Patent No. 11,517,545 (“Treatment of Moderate and Severe Gastroparesis”), which was issued… Read more . . .
-
Oragenics announced that it has raised approximately $16.5 million in a Series H funding round, with proceeds going toward repayment of a $3 million bridge loan and continued development of the company’s OPN-002 neurosteroid nasal… Read more . . .
-
German startup Ebenbuild has received a €2.3 million grant plus a commitment for up to an additional €10 million in future investments from the European Innovation Council (EIC) Accelerator program, the company said. The funding… Read more . . .
-
Beckley Psytech and atai Life Sciences have announced that a Phase 2b trial of Beckley’s BPL-003 intranasal mebufotenin (5-MeO-DMT) in patients with treatment-resistant depression met its primary endpoint, demonstrating a significant reduction in symptoms of depression… Read more . . .
-
Intranasal drug developer Vistagen has announced the appointment of Elissa Cote as Chief Corporate Development Officer. According to her LinkedIn page, Cote served as a strategic advisor to Narcan nasal spray developer Emergent Biosolutions from January 2023 to… Read more . . .
-
According to Theravance Biopharma, a marketing application submitted to the Chinese National Medical Products Administration (NMPA) by Viatris for Yupelri revefenacin inhalation solution for the treatment of COPD has been approved. In November 2023, Theravance and Viatris announced… Read more . . .
-
Bryn Pharma announced that it has initiated a PK/PD trial of its epinephrine spray in an updated delivery device, with topline data expected in the third quarter of this year. The company said that the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK